Keck Hospital of USC

The Society of Radiologists in Ultrasound convened a multidisciplinary panel of experts in the field of vascular ultrasonography (US) to come to a consensus regarding Doppler US for assistance in the diagnosis of carotid artery stenosis. The panel's consensus statement is believed to represent a reasonable position on the basis of analysis of available literature and panelists' experience. Key elements of the statement include the following: (a) All internal carotid artery (ICA) examinations should be performed with gray-scale, color Doppler, and spectral Doppler US. (b) The degree of stenosis determined at gray-scale and Doppler US should be stratified into the categories of normal (no stenosis), <50% stenosis, 50%-69% stenosis, > or =70% stenosis to near occlusion, near occlusion, and total occlusion. (c) ICA peak systolic velocity (PSV) and presence of plaque on gray-scale and/or color Doppler images are primarily used in diagnosis and grading of ICA stenosis; two additional parameters, ICA-to-common carotid artery PSV ratio and ICA end-diastolic velocity may also be used when clinical or technical factors raise concern that ICA PSV may not be representative of the extent of disease. (d) ICA should be diagnosed as (i) normal when ICA PSV is less than 125 cm/sec and no plaque or intimal thickening is visible; (ii) <50% stenosis when ICA PSV is less than 125 cm/sec and plaque or intimal thickening is visible; (iii) 50%-69% stenosis when ICA PSV is 125-230 cm/sec and plaque is visible; (iv) > or =70% stenosis to near occlusion when ICA PSV is greater than 230 cm/sec and visible plaque and lumen narrowing are seen; (v) near occlusion when there is a markedly narrowed lumen at color Doppler US; and (vi) total occlusion when there is no detectable patent lumen at gray-scale US and no flow at spectral, power, and color Doppler US. (e) The final report should discuss velocity measurements and gray-scale and color Doppler findings. Study limitations should be noted when they exist. The conclusion should state an estimated degree of ICA stenosis as reflected in the above categories. The panel also considered various technical aspects of carotid US and methods for quality assessment and identified several important unanswered questions meriting future research.

Acinetobacter is a complex genus, and historically, there has been confusion about the existence of multiple species. The species commonly cause nosocomial infections, predominantly aspiration pneumonia and catheter-associated bacteremia, but can also cause soft tissue and urinary tract infections. Community-acquired infections by Acinetobacter spp. are increasingly reported. Transmission of Acinetobacter and subsequent disease is facilitated by the organism's environmental tenacity, resistance to desiccation, and evasion of host immunity. The virulence properties demonstrated by Acinetobacter spp. primarily stem from evasion of rapid clearance by the innate immune system, effectively enabling high bacterial density that triggers lipopolysaccharide (LPS)-Toll-like receptor 4 (TLR4)-mediated sepsis. Capsular polysaccharide is a critical virulence factor that enables immune evasion, while LPS triggers septic shock. However, the primary driver of clinical outcome is antibiotic resistance. Administration of initially effective therapy is key to improving survival, reducing 30-day mortality threefold. Regrettably, due to the high frequency of this organism having an extreme drug resistance (XDR) phenotype, early initiation of effective therapy is a major clinical challenge. Given its high rate of antibiotic resistance and abysmal outcomes (up to 70% mortality rate from infections caused by XDR strains in some case series), new preventative and therapeutic options for Acinetobacter spp. are desperately needed.

Summary: The minfi package is widely used for analyzing Illumina DNA methylation array data. Here we describe modifications to the minfi package required to support the HumanMethylationEPIC ('EPIC') array from Illumina. We discuss methods for the joint analysis and normalization of data from the HumanMethylation450 ('450k') and EPIC platforms. We introduce the single-sample Noob ( ssNoob ) method, a normalization procedure suitable for incremental preprocessing of individual methylation arrays and conclude that this method should be used when integrating data from multiple generations of Infinium methylation arrays. We show how to use reference 450k datasets to estimate cell type composition of samples on EPIC arrays. The cumulative effect of these updates is to ensure that minfi provides the tools to best integrate existing and forthcoming Illumina methylation array data. Availability and Implementation: The minfi package version 1.19.12 or higher is available for all platforms from the Bioconductor project. Contact: khansen@jhsph.edu. Supplementary information: Supplementary data are available at Bioinformatics online.

Abstract Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40–50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes 1 . Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel 2 ) account for 40% (45%) of phenotypic variance in populations of European ancestry but only around 10–20% (14–24%) in populations of other ancestries. Effect sizes, associated regions and gene prioritization are similar across ancestries, indicating that reduced prediction accuracy is likely to be explained by linkage disequilibrium and differences in allele frequency within associated regions. Finally, we show that the relevant biological pathways are detectable with smaller sample sizes than are needed to implicate causal genes and variants. Overall, this study provides a comprehensive map of specific genomic regions that contain the vast majority of common height-associated variants. Although this map is saturated for populations of European ancestry, further research is needed to achieve equivalent saturation in other ancestries.

INTRODUCTION The brain is responsible for cognition, behavior, and much of what makes us uniquely human. The development of the brain is a highly complex process, and this process is reliant on precise regulation of molecular and cellular events grounded in the spatiotemporal regulation of the transcriptome. Disruption of this regulation can lead to neuropsychiatric disorders. RATIONALE The regulatory, epigenomic, and transcriptomic features of the human brain have not been comprehensively compiled across time, regions, or cell types. Understanding the etiology of neuropsychiatric disorders requires knowledge not just of endpoint differences between healthy and diseased brains but also of the developmental and cellular contexts in which these differences arise. Moreover, an emerging body of research indicates that many aspects of the development and physiology of the human brain are not well recapitulated in model organisms, and therefore it is necessary that neuropsychiatric disorders be understood in the broader context of the developing and adult human brain. RESULTS Here we describe the generation and analysis of a variety of genomic data modalities at the tissue and single-cell levels, including transcriptome, DNA methylation, and histone modifications across multiple brain regions ranging in age from embryonic development through adulthood. We observed a widespread transcriptomic transition beginning during late fetal development and consisting of sharply decreased regional differences. This reduction coincided with increases in the transcriptional signatures of mature neurons and the expression of genes associated with dendrite development, synapse development, and neuronal activity, all of which were temporally synchronous across neocortical areas, as well as myelination and oligodendrocytes, which were asynchronous. Moreover, genes including MEF2C , SATB2 , and TCF4 , with genetic associations to multiple brain-related traits and disorders, converged in a small number of modules exhibiting spatial or spatiotemporal specificity. CONCLUSION We generated and applied our dataset to document transcriptomic and epigenetic changes across human development and then related those changes to major neuropsychiatric disorders. These data allowed us to identify genes, cell types, gene coexpression modules, and spatiotemporal loci where disease risk might converge, demonstrating the utility of the dataset and providing new insights into human development and disease. Spatiotemporal dynamics of human brain development and neuropsychiatric risks. Human brain development begins during embryonic development and continues through adulthood (top). Integrating data modalities (bottom left) revealed age- and cell type–specific properties and global patterns of transcriptional dynamics, including a late fetal transition (bottom middle). We related the variation in gene expression (brown, high; purple, low) to regulatory elements in the fetal and adult brains, cell type–specific signatures, and genetic loci associated with neuropsychiatric disorders (bottom right; gray circles indicate enrichment for corresponding features among module genes). Relationships depicted in this panel do not correspond to specific observations. CBC, cerebellar cortex; STR, striatum; HIP, hippocampus; MD, mediodorsal nucleus of thalamus; AMY, amygdala.

The fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO "Blue Book"), published in 2022, contains significant revisions. This review summarises the most relevant changes for renal, penile, and testicular tumours. In keeping with other volumes in the fifth edition series, the WHO classification of urogenital tumours follows a hierarchical classification and lists tumours by site, category, family, and type. The section "essential and desirable diagnostic criteria" included in the WHO fifth edition represents morphologic diagnostic criteria, combined with immunohistochemistry and relevant molecular tests. The global introduction of massive parallel sequencing will result in a diagnostic shift from morphology to molecular analyses. Therefore, a molecular-driven renal tumour classification has been introduced, taking recent discoveries in renal tumour genomics into account. Such novel molecularly defined epithelial renal tumours include SMARCB1-deficient medullary renal cell carcinoma (RCC), TFEB-altered RCC, Alk-rearranged RCC, and ELOC-mutated RCC. Eosinophilic solid and cystic RCC is a novel morphologically defined RCC entity. The diverse morphologic patterns of penile squamous cell carcinomas are grouped as human papillomavirus (HPV) associated and HPV independent, and there is an attempt to simplify the morphologic classification. A new chapter with tumours of the scrotum has been introduced. The main nomenclature of testicular tumours is retained, including the use of the term "germ cell neoplasia in situ" (GCNIS) for the preneoplastic lesion of most germ cell tumours and division from those not derived from GCNIS. Nomenclature changes include replacement of the term "primitive neuroectodermal tumour" by "embryonic neuroectodermal tumour" to separate these tumours clearly from Ewing sarcoma. The term "carcinoid" has been changed to "neuroendocrine tumour", with most examples in the testis now classified as "prepubertal type testicular neuroendocrine tumour".

Abstract Post-acute infection syndromes may develop after acute viral disease 1 . Infection with SARS-CoV-2 can result in the development of a post-acute infection syndrome known as long COVID. Individuals with long COVID frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions 2–4 . However, the biological processes that are associated with the development and persistence of these symptoms are unclear. Here 275 individuals with or without long COVID were enrolled in a cross-sectional study that included multidimensional immune phenotyping and unbiased machine learning methods to identify biological features associated with long COVID. Marked differences were noted in circulating myeloid and lymphocyte populations relative to the matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with long COVID. Furthermore, higher antibody responses directed against non-SARS-CoV-2 viral pathogens were observed among individuals with long COVID, particularly Epstein–Barr virus. Levels of soluble immune mediators and hormones varied among groups, with cortisol levels being lower among participants with long COVID. Integration of immune phenotyping data into unbiased machine learning models identified the key features that are most strongly associated with long COVID status. Collectively, these findings may help to guide future studies into the pathobiology of long COVID and help with developing relevant biomarkers.

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a writing group to develop a consensus statement on the management of type 1 diabetes in adults. The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycemia, behavioral considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management, and future perspectives. Although we discuss the schedule for follow-up examinations and testing, we have not included the evaluation and treatment of the chronic microvascular and macrovascular complications of diabetes as these are well-reviewed and discussed elsewhere. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this but rather aimed to highlight the major areas that health care professionals should consider when managing adults with type 1 diabetes. Though evidence-based where possible, the recommendations in the report represent the consensus opinion of the authors.

In Alzheimer disease (AD), amyloid β peptide (Aβ) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates Aβ-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked Aβ binding to the V domain of RAGE and inhibited Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APPsw/0 mice overexpressing human Aβ-precursor protein, a transgenic mouse model of AD with established Aβ pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating Aβ40 and Aβ42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited β-secretase activity and Aβ production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced Aβ40 and Aβ42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APPsw/0 mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of Aβ-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.

PURPOSE: In the Children's Oncology Group, risk group assignment for neuroblastoma is critical for therapeutic decisions, and patients are stratified by International Neuroblastoma Staging System stage, MYCN status, ploidy, Shimada histopathology, and diagnosis age. Age less than 365 days has been associated with favorable outcome, but recent studies suggest that older age cutoff may improve prognostic precision. METHODS: To identify the optimal age cutoff, we retrospectively analyzed data from the Pediatric Oncology Group biology study 9047 and Children's Cancer Group studies 321p1-p4, 3881, 3891, and B973 on 3,666 patients (1986 to 2001) with documented ages and follow-up data. Twenty-seven separate analyses, one for each different age cutoff (adjusting for MYCN and stage), tested age influence on outcome. The cutoff that maximized outcome difference between younger and older patients was selected. RESULTS: Thirty-seven percent of patients were younger than 365 days, and 64% were > or = 365 days old (4-year event-free survival [EFS] rate +/- SE: 83% +/- 1% [n = 1,339] and 45% +/- 1% [n = 2,327], respectively; P < .0001). Graphical analyses revealed the continuous nature of the prognostic contribution of age to outcome. The optimal 460-day cutoff we selected maximized the outcome difference between younger and older patients. Forty-three percent were younger than 460 days, and 57% were > or = 460 days old (4-year EFS rate +/- SE: 82% +/- 1% [n = 1,589] and 42% +/- 1% [n = 2,077], respectively; P < .0001). Using a 460-day cutoff (assuming stage 4, MYCN-amplified patients remain high-risk), 5% of patients (365 to 460 days: 4-year EFS 92% +/- 3%; n = 135) fell into a lower risk group. CONCLUSION: The prognostic contribution of age to outcome is continuous in nature. Within clinically relevant risk stratification, statistical support exists for an age cutoff of 460 days.

BACKGROUND: Cardiac pacemakers are limited by device-related complications, notably infection and problems related to pacemaker leads. We studied a miniaturized, fully self-contained leadless pacemaker that is nonsurgically implanted in the right ventricle with the use of a catheter. METHODS: In this multicenter study, we implanted an active-fixation leadless cardiac pacemaker in patients who required permanent single-chamber ventricular pacing. The primary efficacy end point was both an acceptable pacing threshold (≤2.0 V at 0.4 msec) and an acceptable sensing amplitude (R wave ≥5.0 mV, or a value equal to or greater than the value at implantation) through 6 months. The primary safety end point was freedom from device-related serious adverse events through 6 months. In this ongoing study, the prespecified analysis of the primary end points was performed on data from the first 300 patients who completed 6 months of follow-up (primary cohort). The rates of the efficacy end point and safety end point were compared with performance goals (based on historical data) of 85% and 86%, respectively. Additional outcomes were assessed in all 526 patients who were enrolled as of June 2015 (the total cohort). RESULTS: The leadless pacemaker was successfully implanted in 504 of the 526 patients in the total cohort (95.8%). The intention-to-treat primary efficacy end point was met in 270 of the 300 patients in the primary cohort (90.0%; 95% confidence interval [CI], 86.0 to 93.2, P=0.007), and the primary safety end point was met in 280 of the 300 patients (93.3%; 95% CI, 89.9 to 95.9; P<0.001). At 6 months, device-related serious adverse events were observed in 6.7% of the patients; events included device dislodgement with percutaneous retrieval (in 1.7%), cardiac perforation (in 1.3%), and pacing-threshold elevation requiring percutaneous retrieval and device replacement (in 1.3%). CONCLUSIONS: The leadless cardiac pacemaker met prespecified pacing and sensing requirements in the large majority of patients. Device-related serious adverse events occurred in approximately 1 in 15 patients. (Funded by St. Jude Medical; LEADLESS II ClinicalTrials.gov number, NCT02030418.).

Abstract Type 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes 1,2 and molecular mechanisms that are often specific to cell type 3,4 . Here, to characterize the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study data from 2,535,601 individuals (39.7% not of European ancestry), including 428,452 cases of T2D. We identify 1,289 independent association signals at genome-wide significance ( P &lt; 5 × 10 −8 ) that map to 611 loci, of which 145 loci are, to our knowledge, previously unreported. We define eight non-overlapping clusters of T2D signals that are characterized by distinct profiles of cardiometabolic trait associations. These clusters are differentially enriched for cell-type-specific regions of open chromatin, including pancreatic islets, adipocytes, endothelial cells and enteroendocrine cells. We build cluster-specific partitioned polygenic scores 5 in a further 279,552 individuals of diverse ancestry, including 30,288 cases of T2D, and test their association with T2D-related vascular outcomes. Cluster-specific partitioned polygenic scores are associated with coronary artery disease, peripheral artery disease and end-stage diabetic nephropathy across ancestry groups, highlighting the importance of obesity-related processes in the development of vascular outcomes. Our findings show the value of integrating multi-ancestry genome-wide association study data with single-cell epigenomics to disentangle the aetiological heterogeneity that drives the development and progression of T2D. This might offer a route to optimize global access to genetically informed diabetes care.

BACKGROUND: Cell and tissue specific gene expression is a defining feature of embryonic development in multi-cellular organisms. However, the range of gene expression patterns, the extent of the correlation of expression with function, and the classes of genes whose spatial expression are tightly regulated have been unclear due to the lack of an unbiased, genome-wide survey of gene expression patterns. RESULTS: We determined and documented embryonic expression patterns for 6,003 (44%) of the 13,659 protein-coding genes identified in the Drosophila melanogaster genome with over 70,000 images and controlled vocabulary annotations. Individual expression patterns are extraordinarily diverse, but by supplementing qualitative in situ hybridization data with quantitative microarray time-course data using a hybrid clustering strategy, we identify groups of genes with similar expression. Of 4,496 genes with detectable expression in the embryo, 2,549 (57%) fall into 10 clusters representing broad expression patterns. The remaining 1,947 (43%) genes fall into 29 clusters representing restricted expression, 20% patterned as early as blastoderm, with the majority restricted to differentiated cell types, such as epithelia, nervous system, or muscle. We investigate the relationship between expression clusters and known molecular and cellular-physiological functions. CONCLUSION: Nearly 60% of the genes with detectable expression exhibit broad patterns reflecting quantitative rather than qualitative differences between tissues. The other 40% show tissue-restricted expression; the expression patterns of over 1,500 of these genes are documented here for the first time. Within each of these categories, we identified clusters of genes associated with particular cellular and developmental functions.

INTRODUCTION: The Oncotype DX assay was recently reported to predict risk for distant recurrence among a clinical trial population of tamoxifen-treated patients with lymph node-negative, estrogen receptor (ER)-positive breast cancer. To confirm and extend these findings, we evaluated the performance of this 21-gene assay among node-negative patients from a community hospital setting. METHODS: A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 and not treated with adjuvant chemotherapy. Cases (n = 220) were patients who died from breast cancer. Controls (n = 570) were breast cancer patients who were individually matched to cases with respect to age, race, adjuvant tamoxifen, medical facility and diagnosis year, and were alive at the date of death of their matched case. Using an RT-PCR assay, archived tumor tissues were analyzed for expression levels of 16 cancer-related and five reference genes, and a summary risk score (the Recurrence Score) was calculated for each patient. Conditional logistic regression methods were used to estimate the association between risk of breast cancer death and Recurrence Score. RESULTS: After adjusting for tumor size and grade, the Recurrence Score was associated with risk of breast cancer death in ER-positive, tamoxifen-treated and -untreated patients (P = 0.003 and P = 0.03, respectively). At 10 years, the risks for breast cancer death in ER-positive, tamoxifen-treated patients were 2.8% (95% confidence interval [CI] 1.7-3.9%), 10.7% (95% CI 6.3-14.9%), and 15.5% (95% CI 7.6-22.8%) for those in the low, intermediate and high risk Recurrence Score groups, respectively. They were 6.2% (95% CI 4.5-7.9%), 17.8% (95% CI 11.8-23.3%), and 19.9% (95% CI 14.2-25.2%) for ER-positive patients not treated with tamoxifen. In both the tamoxifen-treated and -untreated groups, approximately 50% of patients had low risk Recurrence Score values. CONCLUSION: In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.

The American Society of Colon and Rectal Surgeons (ASCRS) is dedicated to ensuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Committee is composed of society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This committee was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus and develop clinical practice guidelines based on the best available evidence. While not proscriptive, these guidelines provide information on which decisions can be made and do not dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. These guidelines should not be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed toward obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all the circumstances presented by the individual patient. METHODOLOGY These guidelines are constructed on the platform of the previously published Practice Parameters for the Treatment of Sigmoid Diverticulitis published by the American Society of Colon and Rectal Surgeons (ASCRS) in 2014.1 A systematic search was conducted under the guidance of an information services librarian. This search strategy is outlined under the search appendices (see Supplemental Digital Content, https://links.lww.com/DCR/B209). The PubMed, EMBASE, Cochrane, and Web of Science databases were searched from January 1, 2013, until October 26, 2019. Relevant manuscripts identified by individual authors were also included. Key word combinations using the MeSH terms including “Diverticulitis,” “Diverticulosis,” “Diverticular,” “Colonic,” “Colon Diverticulosis,” “Surgery,” “Medical Therapy,” “Antibiotics,” “Probiotics,” “Laparoscopic Lavage,” “Mesalamine,” “Rifaximin,” and “Surgery” were performed. The search was limited to English language abstracts with human subjects. A directed search of references embedded in the candidate publications was also performed. Emphasis was placed on prospective trials, meta-analyses, systematic reviews, and practice guidelines. Peer-reviewed observational studies and retrospective studies were included when higher-quality evidence was insufficient. In brief, a total of 4885 unique journal titles were identified. Initial review of the search results led to the exclusion of 4223 titles based on irrelevance of the title or because they consisted of a case report, letter to the editor, or nonsystematic review. A review of the remaining 662 titles included assessment of the full-length articles. This led to exclusion of an additional 494 titles for which similar but higher-level evidence was available. The remaining 168 titles were considered for grading of the recommendations (Fig. 1). The final source material used was evaluated for the methodological quality, the evidence base was examined, and a treatment guideline was formulated by the subcommittee for this guideline. The final grade of recommendation and level of evidence for each statement were determined using the Grades of Recommendation, Assessment, Development, and Evaluation system (Table 1).2 When agreement was incomplete regarding the evidence base or treatment guideline, consensus from the committee chair, vice chair, and 2 assigned reviewers determined the outcome. Members of the ASCRS Clinical Practice Guidelines Committee worked in joint production of these guidelines from inception to publication. Recommendations formulated by the subcommittee were reviewed by the entire Clinical Practice Guidelines Committee. The submission was peer-reviewed by Diseases of the Colon & Rectum and the final recommendations were approved by the ASCRS Executive Council. In general, each ASCRS Clinical Practice Guideline is updated every 5 years. No funding was received for preparing this guideline and the authors have declared no competing interests related to this material.TABLE 1.: The GRADE System: grading recommendationsFIGURE 1.: PRISMA literature search flow sheet.The terms uncomplicated and complicated diverticulitis, symptomatic uncomplicated diverticular disease (SUDD), and recurrent diverticulitis are used throughout this document. For purposes of this guideline, complicated diverticulitis is defined as diverticulitis associated with uncontained, free perforation with a systemic inflammatory response, fistula, abscess, stricture, or obstruction. Micro-perforation with small amounts of contained, extraluminal gas, in the absence of a systemic inflammatory response, is not considered complicated diverticulitis. Uncomplicated diverticulitis is defined as diverticulitis that is not associated with any of the aforementioned features.3 Symptomatic uncomplicated diverticular disease is defined as diverticulosis with associated chronic abdominal pain in the absence of clinically overt colitis.4 the recurrent diverticulitis no and the studies reviewed in this guideline used and defined The of diverticular disease in the A using from the that the of for diverticulitis from of in to a of of in These authors that were for diverticulitis this with an of from the and the and that in were in the associated with a of diverticular and that in were associated with a of diverticulitis and of these patients were was associated with a of of and a of treatment of The authors used updated from the same 2 and that in were patients with diverticular disease in the demonstrated that the of from to and and that the of these was in of diverticulitis have recommendations for the clinical management of these with diverticular disease are as of to the for diverticulitis from in to in In patients are the of patients an for diverticulitis from of to of and an in the use of and in the management of This the treatment for patients with diverticulitis. diverticular disease can any of the on and of to the management of patients with diverticulitis, are the of these guidelines and are addressed in ASCRS clinical practice The of a patient with diverticulitis should a and and of recommendation based on related to diverticulitis and or are for fistula, and is for and abdominal can be in the to when patients with diverticulitis and and have as of diverticulitis as a of complicated diverticulitis in case in an to a that can patients who have complicated of the are small and the in retrospective of patients with of diverticulitis, uncomplicated from complicated diverticulitis and the of and free on was associated with a of In a of demonstrated that was to patients with uncomplicated and complicated of patients demonstrated that was associated with diverticulitis a uncomplicated diverticulitis from complicated diverticulitis as was abdominal and this a for complicated diverticulitis of studies are to the of in the of diverticulitis the limited evidence not a management of the and is the in the assessment of diverticulitis. of recommendation based on a to diverticulitis, disease and a treatment or is and specific for for abdominal including diverticulitis as as that can the associated with diverticulitis abscess, fistula, and extraluminal and and can patients to The of the of the grade of on with the of of management in the and with as the of and the of and and can be in the of a patient with diverticulitis when is not available or is of recommendation based on and be in patients with a can be or in can be to of pain that can diverticulitis when the is in can complicated diverticulitis and should not be the this is is included as a in the practice guidelines of is and in patients be can also be in patients in is and be from patients with uncomplicated diverticulitis can be of recommendation based on high-quality the use of the treatment for patients with diverticulitis. The of diverticulitis because evidence that diverticulitis is an inflammatory that can in a of as as systematic have no in of patients with uncomplicated diverticulitis with or The for in uncomplicated assigned with uncomplicated diverticulitis to or and and no the treatment in terms of or to This published a of this a of the authors no the 2 in terms of for diverticulitis, or quality of The from The the of patients with of diverticulitis with patients with uncomplicated diverticulitis were assigned to a of of treatment by or in an and the was to The to for the treatment was in the were no the treatment in terms of the of or but the a of of were no the 2 with to recurrent diverticulitis or or for A review also no in patients with uncomplicated diverticulitis with or These studies that a of patients with uncomplicated diverticulitis can be is to that all of the patients included in these studies were and diverticular disease and have also demonstrated that an can be in the A of systematic and have also this A of studies that included patients the of treatment with and studies were trials, 2 were prospective and 5 were retrospective The authors that were no the 2 in terms of of treatment of diverticulitis, for or Treatment was to in patients with associated A retrospective of patients with disease that with a a of treatment when of studies observational management and treatment in patients and that were no the in terms of and when the authors trials, in the observational in the as a these that not be in patients with diverticulitis. treatment of diverticulitis of recommendation based on the 2 the of in uncomplicated diverticulitis, was and is a of the used to all of this The use of to be for patients with of systemic or of the of included patients with disease and the use of to be in all of the A of patients with uncomplicated diverticulitis a of treatment to a and the was as as the of patients of for diverticulitis and demonstrated no clinical the was a associated with A of studies also was no in treatment or when the of diverticulitis was with is for patients with in of recommendation based on diverticulitis with in to of patients who with diverticulitis. treatment with or in with is in to of Treatment is defined as or a recurrent treatment for is in treatment can be in the When this should be in patients with have a to is no and of treatment of diverticular from to of is who do not have a for or who do not to treatment including should be considered for surgery. can be considered in and are to the of diverticulitis. of recommendation based on The of to diverticulosis and diverticulitis is not but is and the In a prospective of from the a in and was associated with an of diverticulitis when to a in and who the of a a of for diverticulitis with in the and the authors the to the of and demonstrated a similar when they of diverticulitis that were identified of defined patients with a as who an in the of the 2 of and an the of and diverticulitis for When all 5 were the of diverticular disease was these authors to a A of have to to recurrent of diverticulitis. a is associated with a of a of diverticulitis, the of in of diverticulitis is a of 5 prospective studies that of diverticular The for an of diverticular disease was for for and for the including and The for a of diverticular disease or was for and for and the authors that is associated with an of diverticular disease and associated The same authors also the of in a of 5 studies and that the for a in was for a of diverticulitis and for a diverticular are as and be as to the of diverticulitis, but the of these in is and are not to the of diverticulitis but be in chronic of recommendation based on that have with to the of diverticulitis and studies the of in demonstrated the of and do not in A of demonstrated no and regarding recurrent diverticulitis not to the of recurrent diverticulitis, a in in patients with A of studies the of in of diverticulitis these In patients were assigned to a with or because of the was to a and the The demonstrated a of recurrent diverticulitis in the in with the retrospective of patients with symptomatic diverticular disease with demonstrated a in disease abdominal pain and and in of including patients that is in obtaining studies have the of on the of diverticulitis, no was A evaluated the of a of and on of defined as the of abdominal pain as for A total of patients were assigned to and for for The authors that and in the of These results must be with because the was of and was no evidence presented regarding of disease as by or inflammatory In general, studies the use of or are and the use of these an of diverticulitis is not of an of complicated diverticulitis, the colon should be evaluated to the a not of recommendation based on with complicated diverticulitis are of an A systematic review and by and demonstrated that the of was in patients with complicated diverticulitis and was in with uncomplicated diverticulitis. systematic review that the of was in patients with complicated diverticulitis and was in with uncomplicated The colon should be evaluated to a in patients who have an of complicated diverticulitis, and this is about the to the of a should be that the this are assigned patients with diverticulitis to the or The no in terms of or related to and the authors that is and under these These should be with because the authors not a or and the results be to a associated with an of on abscess, the of the inflammatory have a and or and systematic review have that patients with uncomplicated diverticulitis on are of or similar to the and not for or clinical is patients with uncomplicated diverticulitis should assessment with treatment of a diverticular abscess, should be of recommendation based on In general, literature that patients who with a diverticular a A of that of these can be and that are patients who do not a under these The recommendation to treatment of an a from the practice that of a or a While the of is an are that the to as of A retrospective from the of and of patients who were with diverticulitis and that patients who presented with a diverticular were to have recurrent diverticulitis and to have a complicated recurrent patients from the and who a diverticular this patients of the remaining The for the patients who not was to A of retrospective studies have that from to an are patients who a diverticular with a In a retrospective review of patients with diverticular patients recurrent diverticulitis an of the the of with the in of patients and of the patients who recurrent diverticulitis patients who not have recurrent diverticulitis the patients who the was A the of patients with an of diverticular abscess, the of were These authors no in treatment which was defined as the of diverticulitis, or for in patients with with in were of treatment 5 or were associated with the for In this and of diverticulitis were associated with the was associated with retrospective review of patients with diverticular with and management a a of of the patients who complicated A studies including patients regarding the of patients who a diverticular demonstrated a diverticulitis and the authors that treatment of a should be with are management of a diverticular abscess, be in with A retrospective review of patients with who of a diverticular and not a 5 patients with uncomplicated diverticulitis and patients recurrent were who were to have an The authors that management management of a diverticular is in In a retrospective review of patients of diverticulitis, patients with complicated disease a patients with uncomplicated disease and an of The authors that the of patients not or and that not be in this they that patients with or who are for should be for patients with diverticulitis complicated by fistula, or of recommendation based on A retrospective review of patients of diverticulitis that patients with an complicated were to have a complicated with patients was uncomplicated In diverticulitis is complicated by or stricture, or is to provide symptomatic extraluminal on is considered complicated and these should in and of dictate a specific the should these with the clinical when on based on is not of recommendation based on diverticulitis patients associated with clinical In terms of a for diverticulitis a used and associated with diverticulitis. These authors identified a to the and that the of the system to diverticulitis. used as an for an of uncomplicated diverticulitis. the regarding the for or for that not the for clinical the literature with patients with patients do not have complicated and databases and systematic that patients are to for diverticulitis, are regarding of in a retrospective of patients a of diverticulitis and a demonstrated that patients a of but a similar of with patients A of patients with diverticulitis demonstrated a of in patients which was to be to a for on patients who have a of recurrent including studies and patients demonstrated a of recurrent diverticulitis in patients and that patients The to from uncomplicated diverticulitis should be of recommendation based on patients with uncomplicated diverticulitis from to and of complicated disease or for from an of diverticulitis, the of with is in of to these patients to to for The practice of to a is not by the literature and should be review of a patients for diverticulitis and demonstrated and the a in the of or This with the that to of are of diverticulitis, the practice of for patients with uncomplicated diverticulitis, because not the of patients who with uncomplicated disease are to have or patients who are for a of uncomplicated diverticulitis are of A review of patients who from of diverticulitis that of patients on to have a for of patients a of the patients or the of each patients of of uncomplicated diverticulitis should the unique to the the and of for related or to including and the of or recurrent abdominal as as patient the of as as related to diverticulitis, in quality of In a prospective of patients who for diverticulitis, patients in retrospective of patients in quality of using a The a of patients with recurrent diverticulitis or abdominal to diverticular patients who with patients in an The was in the this was because of with and of and the to have quality of in with the The also and pain A using the from these of patients treatment a in the and this to 5 years. The authors that in patients with diverticulitis was The which and observational for the management of diverticular disease published and and who the of and were considered to have to of patients or 2 on which was who pain on the the of were to have who of on were also to have these that patients have an of uncomplicated diverticulitis. In is in an of diverticulitis. The to with should be including and about of diverticulitis and or of The to from uncomplicated diverticulitis in patients should be of recommendation based on patients are a unique of patients that in terms of an for diverticulitis. A retrospective review of the patients with patients who for that the but the of and were in the The to with in the for patients should these A retrospective review of a a patients with patients who management of of diverticulitis with a of The of recurrent diverticulitis was similar in of patients of patients who a as or were to have a or a complicated the of was the 2 The authors to and the of patients for uncomplicated diverticulitis do not A retrospective review patients who with patients for was no in the the the were in patients in These authors that management of patients with uncomplicated disease is and the ASCRS clinical practice guideline that a for in these small of patients and patients on for patients of diverticulitis and the A retrospective review that included patients with chronic disease and patients these conditions who were treatment of diverticulitis that the patients a of diverticulitis with perforation The authors that because of the and associated with in patients with should be for patients be The literature a for a of uncomplicated diverticulitis in patients is not or not the specific of should treatment recommendations is because of the literature the of is for patients with or for in management of diverticulitis of recommendation based on the of patients for diverticulitis to to an for patients with or systemic inflammatory to or who are These patients and In a retrospective for diverticulitis in the was of included or and an with or of these a of and is a small of patients with diverticulitis, with but who be in the In these can be made to an or to an to to and patients or a For patients who do not from a clinical with or with abdominal pain or the to are to they not have evidence of a systemic inflammatory abdominal to or to management of and be clinical judgment the for treatment in this the to should patient and of recommendation based on the colon is the the by a with or a or or by an with a a procedure was considered for in diverticulitis, is an of and and and with or the of the available this clinical practice guideline recommendation from a recommendation based on evidence in the guideline to a recommendation based on evidence assigned patients with diverticulitis and to and or but this was to in patients were assigned to the and to the These authors no in and patients or and were patients who a procedure of from The and similar In trials, patients with or diverticulitis were assigned to a with studies no in and but with were in the in the and were in the in and In to the was because an that with The was to patients by the of the In the of the published This assigned patients with or disease to procedure with with or The to was to the of the was in patients with procedure were no the and in terms of or the These authors that a is to a procedure for or of including of the studies and that was associated with of and included patients from observational studies and demonstrated that a in with the procedure including not in or when and A including of the for diverticulitis and that also demonstrated that for procedure were a of including and Sigmoid with similar of and in with the who and were to be with patients who the procedure and related to These authors updated to the results of the and that patients were to be were no in or but was a of when patients who in with patients who These authors that is the procedure of for and diverticulitis in patients and that is no additional for or to this efforts should be on of this evidence A of the patients who for diverticulitis that patients who chronic and were in with patients who with and a for on patients who with not have a of These authors that with to be a to procedure in the a the of for diverticulitis is the of under these circumstances but regarding patients for diverticulitis patients who a procedure or with and no in and when the of was a toward and when was not in the of a The small of patients who with in this the of the that have regarding or not to an in the of for diverticulitis the of the and the of this in A that used a patients who or procedure with patients who with a This demonstrated a of when a in with In this a was defined as a who was in Colon and Rectal to is a and to be in recommendations regarding the of of this The to and to in the of a should be as the the associated with Parameters and procedure patient and as or chronic and be a for procedure in with and in not be considered as a to for diverticulitis quality of the procedure with patients who with which was to the of an and the is not in patients with should be in this of recommendation based on high-quality The of evaluated by retrospective and and that with The 2 and the and were the which the to results. In all disease was and the of patients with not in patients with diverticulitis, these patients should be with In patients with is is associated with of in with of recommendation based on high-quality The of used in the this was not and the were and The of of and management of the of diverticular perforation the to the used a of and the used the of and the In the an demonstrated a of in the in with the the of this was not and of These led to of the by the and The and was the and of patients not any or and of patients a In the the of patients with was the and also The of and were in the The of and Colon was in patients and in 2 patients who In the when were was no the and When all the treatment were the in a of or of A of and systematic have to the results of studies regarding A review of patients from the and studies to that was used in patients with grade and and were similar the The of included of and of based on the results of was associated with of abscess, and of patients a or in to The of in the was patients who a a of is to in this of patients who a patients with can be with and the and of a associated with a is also associated with an of or recurrent diverticulitis, and an fistula, and are to for patients who from and to the Surgeons should be of the clinical and of associated with this and should be to as The of should the entire colon with of colon and of recommendation based on The of management are the same when for complicated and uncomplicated diverticular the of colon is is on the specific clinical the should be in colon evidence of is not to all The should be in a because to the is associated with a of recurrent be to the to a rectal can also additional and be to rectal that can with the and with an studies that a with of the the of to a with this When expertise is a to for diverticulitis is of recommendation based on high-quality The of in a in the management of diverticular and in the of for diverticular disease have the literature is retrospective in and to is evidence the use of when the this is a for individual as abdominal and the of to the of a for is the use of for and A retrospective of patients management of complicated diverticulitis demonstrated a in and in patients who a in with who an A using also demonstrated and in patients who an procedure with an also to the management of diverticular disease and that clinical are similar to A with that was of with the including from the the use of and also that was with were A retrospective from the of patients who for diverticular disease that patients who of and in with patients who this used to for in the not be retrospective diverticulitis with were no in to 2 of or use of the were when to In a retrospective of patients for or diverticulitis, that with was associated with of and in with with were no in to of of of or the was associated with

Neurogenic orthostatic hypotension (nOH) is common in patients with neurodegenerative disorders such as Parkinson's disease, multiple system atrophy, pure autonomic failure, dementia with Lewy bodies, and peripheral neuropathies including amyloid or diabetic neuropathy. Due to the frequency of nOH in the aging population, clinicians need to be well informed about its diagnosis and management. To date, studies of nOH have used different outcome measures and various methods of diagnosis, thereby preventing the generation of evidence-based guidelines to direct clinicians towards 'best practices' when treating patients with nOH and associated supine hypertension. To address these issues, the American Autonomic Society and the National Parkinson Foundation initiated a project to develop a statement of recommendations beginning with a consensus panel meeting in Boston on November 7, 2015, with continued communications and contributions to the recommendations through October of 2016. This paper summarizes the panel members' discussions held during the initial meeting along with continued deliberations among the panel members and provides essential recommendations based upon best available evidence as well as expert opinion for the (1) screening, (2) diagnosis, (3) treatment of nOH, and (4) diagnosis and treatment of associated supine hypertension.

Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and ethnic disparities. We report a large transancestral association study of SLE using Immunochip genotype data from 27,574 individuals of European (EA), African (AA) and Hispanic Amerindian (HA) ancestry. We identify 58 distinct non-HLA regions in EA, 9 in AA and 16 in HA (∼50% of these regions have multiple independent associations); these include 24 novel SLE regions ( P &lt;5 × 10 −8 ), refined association signals in established regions, extended associations to additional ancestries, and a disentangled complex HLA multigenic effect. The risk allele count (genetic load) exhibits an accelerating pattern of SLE risk, leading us to posit a cumulative hit hypothesis for autoimmune disease. Comparing results across the three ancestries identifies both ancestry-dependent and ancestry-independent contributions to SLE risk. Our results are consistent with the unique and complex histories of the populations sampled, and collectively help clarify the genetic architecture and ethnic disparities in SLE.

UNLABELLED: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist(®)), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. FUNDING: Bayer HealthCare.

The objective of this study was to test the efficacy and suitability of virtual reality (VR) as a pain distraction for pediatric intravenous (i.v.) placement. Twenty children (12 boys, 8 girls) requiring i.v. placement for a magnetic resonance imaging/computed tomography (MRI/CT) scan were randomly assigned to two conditions: (1) VR distraction using Street Luge (5DT), presented via a head-mounted display, or (2) standard of care (topical anesthetic) with no distraction. Children, their parents, and nurses completed self-report questionnaires that assessed numerous health-related outcomes. Responses from the Faces Pain Scale-Revised indicated a fourfold increase in affective pain within the control condition; by contrast, no significant differences were detected within the VR condition. Significant associations between multiple measures of anticipatory anxiety, affective pain, i.v. pain intensity, and measures of past procedural pain provided support for the complex interplay of a multimodal assessment of pain perception. There was also a sufficient amount of evidence supporting the efficacy of Street Luge as a pediatric pain distraction tool during i.v. placement: an adequate level of presence, no simulator sickness, and significantly more child-, parent-, and nurse-reported satisfaction with pain management. VR pain distraction was positively endorsed by all reporters and is a promising tool for decreasing pain, and anxiety in children undergoing acute medical interventions. However, further research with larger sample sizes and other routine medical procedures is warranted.

The continuing enhancement of the surgical environment in the digital age has led to a number of innovations being highlighted as potential disruptive technologies in the surgical workplace. Augmented reality (AR) and virtual reality (VR) are rapidly becoming increasingly available, accessible and importantly affordable, hence their application into healthcare to enhance the medical use of data is certain. Whether it relates to anatomy, intraoperative surgery, or post-operative rehabilitation, applications are already being investigated for their role in the surgeons armamentarium. Here we provide an introduction to the technology and the potential areas of development in the surgical arena.